Paola Zanovello

List of Publications by Year
in descending order

112 papers	11,297 citations	66343 42 h-index	28297 105 g-index
117 all docs	117 docs citations	117 times ranked	14151 citing authors

#	Article	IF	Citations
1	Regulation of immune responses by L-arginine metabolism. Nature Reviews Immunology, 2005, 5, 641-654.	22.7	1,516
2	Tumor-Induced Tolerance and Immune Suppression Depend on the C/EBPÎ² Transcription Factor. Immunity, 2010, 32, 790-802.	14.3	782
3	Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. Journal of Clinical Investigation, 2006, 116, 2777-2790.	8.2	723
4	Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism. Journal of Immunology, 2002, 168, 689-695.	0.8	585
5	Myeloid-derived suppressor cell heterogeneity and subset definition. Current Opinion in Immunology, 2010, 22, 238-244.	5.5	579
6	Tumorâ€induced tolerance and immune suppression by myeloid derived suppressor cells. Immunological Reviews, 2008, 222, 162-179.	6.0	569
7	L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends in Immunology, 2003, 24, 301-305.	6.8	508
8	Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. Blood, 2000, 96, 3838-3846.	1.4	474
9	IL-4-Induced Arginase 1 Suppresses Alloreactive T Cells in Tumor-Bearing Mice. Journal of Immunology, 2003, 170, 270-278.	0.8	445
10	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood, 2011, 118, 2254-2265.	1.4	328
11	Derangement of immune responses by myeloid suppressor cells. Cancer Immunology, Immunotherapy, 2004, 53, 64-72.	4.2	321
12	IL4RÎ±+ Myeloid-Derived Suppressor Cell Expansion in Cancer Patients. Journal of Immunology, 2009, 182, 6562-6568.	0.8	287
13	Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4185-4190.	7.1	271
14	Tumor-Induced Immune Dysfunctions Caused by Myeloid Suppressor Cells. Journal of Immunotherapy, 2001, 24, 431-446.	2.4	234
15	Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood, 2011, 117, 7053-7062.	1.4	199
16	Immortalized Myeloid Suppressor Cells Trigger Apoptosis in Antigen-Activated T Lymphocytes. Journal of Immunology, 2000, 165, 6723-6730.	0.8	146
17	T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell, 2016, 30, 377-390.	16.8	141
18	Impact of microRNAs on regulatory networks and pathways in human colorectal carcinogenesis and development of metastasis. BMC Genomics, 2013, 14, 589.	2.8	140

#	Article	IF	Citations
19	Role of arginine metabolism in immunity and immunopathology. Immunobiology, 2008, 212, 795-812.	1.9	133
20	miR-142-3p Prevents Macrophage Differentiation during Cancer-Induced Myelopoiesis. Immunity, 2013, 38, 1236-1249.	14.3	127
21	Extracellular ATP as a possible mediator of cell-mediated cytotoxicity. Trends in Immunology, 1990, 11, 274-277.	7.5	116
22	Small Noncoding RNAs in Cells Transformed by Human T-Cell Leukemia Virus Type 1: a Role for a tRNA Fragment as a Primer for Reverse Transcriptase. Journal of Virology, 2014, 88, 3612-3622.	3.4	116
23	Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Letters, 2008, 267, 216-225.	7.2	103
24	IFN-Î³-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine, 2010, 28, 3548-3557.	3.8	98
25	Common Cancer Biomarkers. Cancer Research, 2006, 66, 2953-2961.	0.9	96
26	A gene expression signature associated with survival in metastatic melanoma. Journal of Translational Medicine, 2006, 4, 50.	4.4	93
27	HYTAD1-p20: A new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 207-215.	1.6	87
28	A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent <i>In vivo</i> Therapeutic Activity. Clinical Cancer Research, 2008, 14, 3598-3606.	7.0	86
29	Formation and Antitumor Activity of PNU-159682, A Major Metabolite of Nemorubicin in Human Liver Microsomes. Clinical Cancer Research, 2005, 11, 1608-1617.	7.0	74
30	Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF Neutralization. Cancer Research, 2011, 71, 4214-4225.	0.9	67
31	PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models. PLoS ONE, 2014, 9, e109427.	2.5	64
32	<i>In vivo</i> Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer. Cancer Research, 2009, 69, 9376-9384.	0.9	61
33	Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors. Cancer Research, 2009, 69, 9385-9394.	0.9	55
34	Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. Blood, 2000, 96, 3838-3846.	1.4	54
35	Survivin in esophageal cancer: An accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. International Journal of Cancer, 2006, 119, 1717-1722.	5.1	53
36	Loss of zfp36 expression in colorectal cancer correlates to wnt/ Î²-catenin activity and enhances epithelial-to-mesenchymal transition through upregulation of zeb1, sox9 and macc1. Oncotarget, 2016, 7, 59144-59157.	1.8	53

#	Article	IF	Citations
37	Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. Oncotarget, 2014, 5, 6611-6619.	1.8	53
38	MAGE,BAGE, andGAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. Cancer, 2001, 91, 1882-1888.	4.1	50
39	Melanoma-restricted genes. Journal of Translational Medicine, 2004, 2, 34.	4.4	50
40	A circulating miRNA assay as a first-line test for prostate cancer screening. British Journal of Cancer, 2016, 114, 1362-1366.	6.4	44
41	Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors. Journal of Immunology, 2010, 184, 5895-5902.	0.8	43
42	An integrative framework identifies alternative splicing events in colorectal cancer development. Molecular Oncology, 2014, 8, 129-141.	4.6	43
43	Large and Dissimilar Repertoire of Melan-A/MART-1-Specific CTL in Metastatic Lesions and Blood of a Melanoma Patient. Journal of Immunology, 2002, 169, 4017-4024.	0.8	42
44	Preventive Vaccination with Telomerase Controls Tumor Growth in Genetically Engineered and Carcinogen-Induced Mouse Models of Cancer. Cancer Research, 2008, 68, 9865-9874.	0.9	42
45	Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opinion on Biological Therapy, 2008, 8, 1265-1294.	3.1	40
46	Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase. Journal of Immunology, 2003, 171, 6396-6405.	0.8	39
47	CTL Response and Protection Against P815 Tumor Challenge in Mice Immunized with DNA Expressing the Tumor-Specific Antigen P815A. Human Gene Therapy, 1997, 8, 1451-1458.	2.7	38
48	Role of microRNAs in HTLV-1 infection and transformation. Molecular Aspects of Medicine, 2010, 31, 367-382.	6.4	37
49	Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells. Cytokine and Growth Factor Reviews, 2017, 36, 99-105.	7.2	37
50	MAGE, BAGE andGAGE gene expression in human rhabdomyosarcomas. International Journal of Cancer, 2001, 93, 85-90.	5.1	36
51	Leukocyte Infiltration in Cancer Creates an Unfavorable Environment for Antitumor Immune Responses: A Novel Target for Therapeutic Intervention. Immunological Investigations, 2006, 35, 327-357.	2.0	36
52	Protein Tyrosine Kinases and Phosphatases Control Apoptosis Induced by Extracellular Adenosine 5â€²-Triphosphate. Biochemical and Biophysical Research Communications, 1996, 218, 344-351.	2.1	35
53	The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Research, 2003, 63, 2158-63.	0.9	34
54	Membrane Form of TNFÎ± Induces both Cell Lysis and Apoptosis in Susceptible Target Cells. Cellular Immunology, 1996, 171, 102-110.	3.0	33

#	Article	IF	Citations
55	Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood, 2010, 115, 1374-1384.	1.4	33
56	HIV-mediated immunodepression: in vitro inhibition of T-lymphocyte proliferative response by ultraviolet-inactivated virus. Clinical Immunology and Immunopathology, 1988, 46, 37-54.	2.0	29
57	Immunotherapy for EBV-associated malignancies. International Journal of Hematology, 2011, 93, 281-293.	1.6	29
58	Paclitaxel-hyaluronan hydrosoluble bioconjugate: Mechanism of action in human bladder cancer cell lines. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1261-1269.	1.6	28
59	Role of Extracellular ATP in Cell-Mediated Cytotoxicity: A Study with ATP-Sensitive and ATP-Resistant Macrophages. Cellular Immunology, 1994, 156, 458-467.	3.0	26
60	Study of Some Early Immunological Parameters in Aging Humans. Gerontology, 1988, 34, 277-283.	2.8	24
61	Differential expression of constitutive and inducible proteasome subunits in human monocyteâ€derived DC differentiated in the presence of IFNâ€<i>Î±</i> or ILâ€4. European Journal of Immunology, 2009, 39, 56-66.	2.9	24
62	Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor Î± Usage by Melanoma-specific CD8+ T Lymphocytes. Cancer Research, 2004, 64, 8068-8076.	0.9	22
63	Biodistribution imaging of a paclitaxel-hyaluronan bioconjugate. Nuclear Medicine and Biology, 2009, 36, 525-533.	0.6	22
64	Silencing of miR-182 is associated with modulation of tumorigenesis through apoptosis induction in an experimental model of colorectal cancer. BMC Cancer, 2019, 19, 821.	2.6	22
65	Reverse immunoediting: When immunity is edited by antigen. Immunology Letters, 2016, 175, 16-20.	2.5	21
66	Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. OncoImmunology, 2016, 5, e1199311.	4.6	21
67	<i>WT1</i> loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. Haematologica, 2018, 103, 266-277.	3.5	21
68	A site-selective hyaluronan-interferonÎ±2a conjugate for the treatment of ovarian cancer. Journal of Controlled Release, 2016, 236, 79-89.	9.9	19
69	Survivin Expression and Prognostic Significance in Pediatric Malignant Peripheral Nerve Sheath Tumors (MPNST). PLoS ONE, 2013, 8, e80456.	2.5	19
70	Individual Analysis of Mice Vaccinated against a Weakly Immunogenic Self Tumor-Specific Antigen Reveals a Correlation between CD8 T Cell Response and Antitumor Efficacy. Journal of Immunology, 2003, 171, 5172-5179.	0.8	18
71	Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer. Oncoscience, 2015, 2, 373-381.	2.2	18
72	T-cell receptor gene transfer by lentiviral vectors in adoptive cell therapy. Expert Opinion on Biological Therapy, 2007, 7, 893-906.	3.1	17

#	Article	IF	Citations
73	miR-22-3p Negatively Affects Tumor Progression in T-Cell Acute Lymphoblastic Leukemia. Cells, 2020, 9, 1726.	4.1	17
74	A coordinate deregulation of microRNAs expressed in mucosa adjacent to tumor predicts relapse after resection in localized colon cancer. Molecular Cancer, 2018, 17, 17.	19.2	15
75	Functional activityin vivo of effector T cell populations III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone. European Journal of Immunology, 1987, 17, 173-178.	2.9	14
76	Predicting Tumor Outcome following Cancer Vaccination by Monitoring Quantitative and Qualitative CD8+ T Cell Parameters. Journal of Immunology, 2006, 176, 1999-2006.	0.8	14
77	Dissecting the Immune Response to Moloney Murine Sarcoma/Leukemia Virus-Induced Tumors by Means of a DNA Vaccination Approach. Journal of Virology, 1999, 73, 2280-2287.	3.4	14
78	A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors. OncoImmunology, 2017, 6, e1304338.	4.6	13
79	Chemotactic Cues for NOTCH1-Dependent Leukemia. Frontiers in Immunology, 2018, 9, 633.	4.8	13
80	Crosstalk between Hedgehog pathway and the glucocorticoid receptor pathway as a basis for combination therapy in T-cell acute lymphoblastic leukemia. Oncogene, 2020, 39, 6544-6555.	5.9	13
81	Role of anti-LFA-1 and anti-ICAM-1 combined mab treatment in the rejection of tumors induced by moloney murine sarcoma virus (M-MSV). International Journal of Cancer, 1995, 61, 355-362.	5.1	12
82	CD45 Regulates Apoptosis Induced by Extracellular Adenosine Triphosphate and Cytotoxic T Lymphocytes. Biochemical and Biophysical Research Communications, 1996, 226, 769-776.	2.1	12
83	Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. , 1996, 65, 847-851.		12
84	Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination. Leukemia, 2021, 35, 984-1000.	7.2	12
85	Synergistic Effect of Extracellular Adenosine 5â€²-Triphosphate and Tumor Necrosis Factor on DNA Degradation. Cellular Immunology, 1993, 152, 110-119.	3.0	11
86	DNA-Based Vaccination against Tumors Expressing the P1A Antigen. Methods, 1999, 19, 187-190.	3.8	11
87	Peritoneal Tumor Carcinomatosis: Pharmacological Targeting with Hyaluronan-Based Bioconjugates Overcomes Therapeutic Indications of Current Drugs. PLoS ONE, 2014, 9, e112240.	2.5	11
88	Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. OncoImmunology, 2017, 6, e1313371.	4.6	11
89	Inhibition of Protein Tyrosine Phosphorylation Prevents T-Cell-Mediated Cytotoxicity. Cellular Immunology, 1994, 159, 294-305.	3.0	10
90	Predictors of immune reconstitution inflammatory syndrome associated with Kaposiâ€™s sarcoma: a case report. Infectious Agents and Cancer, 2016, 11, 5.	2.6	9

#	Article	IF	Citations
91	Circulating miRNAâ€375 as a potential novel biomarker for active Kaposiâ€™s sarcoma in AIDS patients. Journal of Cellular and Molecular Medicine, 2019, 23, 1486-1494.	3.6	8
92	Resistance of lymphokine-activated T lymphocytes to cell-mediated cytotoxicity. Cellular Immunology, 1989, 122, 450-460.	3.0	7
93	<i>In Vitro</i>Cytotoxic Effects of Extracellular ATP. ATLA Alternatives To Laboratory Animals, 1992, 20, 66-70.	1.0	7
94	Functional Avidityâ€“Driven Activation-Induced Cell Death Shapes CTL Immunodominance. Journal of Immunology, 2014, 193, 4704-4711.	0.8	7
95	Human miRNome profiling in colorectal cancer and liver metastasis development. Genomics Data, 2014, 2, 184-188.	1.3	7
96	LACK OF T-CELL MEDIATED CYTOTOXICITY IN M-MSV SYSTEM DEPENDING ON H-2 HAPLOTYPES. International Journal of Immunogenetics, 1979, 6, 341-351.	1.2	6
97	Tolerance to viral antigens in Mov-13 mice carrying endogenized moloney-murine leukemia virus. Cellular Immunology, 1984, 83, 379-388.	3.0	6
98	Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. Cancer Immunology, Immunotherapy, 1992, 35, 27-32.	4.2	6
99	The MicroRNA Regulatory Network in Normal- and HTLV-1-Transformed T Cells. Advances in Cancer Research, 2012, 113, 45-83.	5.0	6
100	Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer. Cancer Immunology, Immunotherapy, 2011, 60, 1639-1645.	4.2	5
101	Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma. Immunology, 2015, 146, 33-49.	4.4	5
102	Impact of Î³-chain cytokines on EBV-specific T cell cultures. Journal of Translational Medicine, 2010, 8, 121.	4.4	4
103	Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. Melanoma Research, 2019, 29, 89-94.	1.2	4
104	Leukemia-cell rejection due to T-region encoded antigens. Immunogenetics, 1981, 12, 433-443.	2.4	3
105	In vitro induction of immunological tolerance. Cellular Immunology, 1989, 124, 187-201.	3.0	3
106	Immune response to Moloney-murine leukemia virus-induced antigens in bone marrow. Immunology Letters, 2011, 138, 79-85.	2.5	3
107	Reconstruction of gene regulatory modules from RNA silencing of IFN-Î± modulators: experimental set-up and inference method. BMC Genomics, 2016, 17, 228.	2.8	3
108	Cancer rejection by the immune system: Forcing the check-points of tumor immune escape. Drug Discovery Today Disease Mechanisms, 2005, 2, 191-197.	0.8	2

#	Article	IF	Citations
109	Responsiveness to Hedgehog Pathway Inhibitors in T-Cell Acute Lymphoblastic Leukemia Cells Is Highly Dependent on 5â€²AMP-Activated Kinase Inactivation. International Journal of Molecular Sciences, 2021, 22, 6384.	4.1	2
110	DNA Immunization in Mice against Virus-Induced Tumor Antigens. Advances in Experimental Medicine and Biology, 1998, 451, 311-314.	1.6	1
111	Extracellular ATP Causes Changes in Plasma Membrane Permeability of Mouse Lymphocytes. Annals of the New York Academy of Sciences, 1990, 603, 427-428.	3.8	0
112	Cell-Permeabilizing Properties of Extracellular ATP in Relation to Lymphocyte-Mediated Cytotoxicity. , 1993, , 314-320.		0